Neurophth Biotechnology Ltd., a fully-integrated genomic medicines company, has opened a new manufacturing facility at the Phase II Suzhou Biomedical Industrial Park (BioBAY) in Suzhou, China.   The 8,000 square-meter gene therapy-focused current good manufacturing practice (cGMP) production facility includes two drug substance production suites, two filling lines, a cell banking suite, a technology transfer laboratory and a quality-control laboratory. Neurophth’s proprietary manufacturing...